JUN and inflammatory bowel disease: By antagonizing the activator protein-1 (AP-1), stat3, and nuclear factor-kappa B signaling pathways, FXR alleviates inflammation and protects impaired intestinal epithelial barrier integrity in inflammatory bowel disease (IBD) [16].